Details
- ●Modalities: small molecules
- ●Therapeutic areas: oncology
- ●Key targets:
- ●Indications: Undisclosed
- ●Funding: Undisclosed
Key considerations
- ●Founded 2025
- ●Reid Hoffman (LinkedIn co-founder) as co-founder + board chair
- ●Siddhartha Mukherjee (Pulitzer-winning author, Columbia) as co-founder
Source: Company website, SEC / Companies House filings, press releases, Crunchbase · biotech.today analysis (Apr 2026)